轻量级视觉变压器与转移学习用于可解释的阿尔茨海默病严重性评估
Ruhika Sharma1,2, Vishal Acharya3,4
1Artificial Intelligence for Computational Biology (AICoB) Laboratory, Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, 176061, Himachal Pradesh, India.
Scientific reports
|December 17, 2025
概括
一个新的深度学习框架,ViTTL,使用MRI扫描准确诊断阿尔茨海默病 (AD). 这种轻量级的工具提供了可解释的结果和高效的部署,以改善患者的治疗结果.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于早期检测以有效管理.
- 目前的诊断方法可能具有侵入性或缺乏可访问性.
- 开发可靠的,非侵入性的工具对于减缓AD进展至关重要.
研究的目的:
- 引入ViTTL,这是一个轻量级的深度学习框架,用于使用MRI数据评估阿尔茨海默氏症的严重程度.
- 评估ViTTL的性能和可解释性.
- 证明临床转化和改善患者治疗结果的潜力.
主要方法:
- ViTTL将视觉转换器 (ViT) 与预训练的卷积神经网络 (CNN) 集成在一起,以从二维MRI切片中提取特征.
- 评估了ViT-DenseNet201模型与人工神经网络 (ANN) 分类器相结合.
- 使用LIME和GRAD-CAM方法实现了可解释性.
主要成果:
- ViT-DenseNet201-ANN模型在OASIS数据集上实现了99.89%的分类准确性.
- 可解释性方法始终强调与AD病理学相关的皮质和海马区域 (子分数:0.85 ± 0.03).
- ViTTL显示了显著的模型大小减少 (83.0 MB到6.47 MB) 和在独立数据集上强大的性能.
结论:
- ViTTL为阿尔茨海默病诊断提供了一个准确,可解释和资源高效的解决方案.
- 该框架的规模缩小和强大的性能表明,在资源有限的临床环境中可能会部署.
- ViTTL对临床翻译有希望,可能改善早期AD检测和患者管理.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.8K
相关概念视频
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
